Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

BACKGROUND: Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of GLP-1ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Yang, Chun-Ting, Yang, Chen-Yi, Ou, Huang-Tz, Kuo, Shihchen
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293792/
https://ncbi.nlm.nih.gov/pubmed/32534570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01053-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados